FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes

Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials While not indicated for weight loss, Mounjaro led to significantly greater weight reductions versus comparators in a key secondary endpoint Mounjaro represents the first new class of diabetes